Advanced Financial Statements From 2010 to 2025
| APTCF Stock | USD 0.0002 0.00 0.00% |
Check Advanced Proteome financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Advanced Proteome's main balance sheet or income statement drivers, such as , as well as many indicators such as . Advanced financial statements analysis is a perfect complement when working with Advanced Proteome Valuation or Volatility modules.
Advanced |
Advanced Proteome Therapeutics Company Price To Earning Analysis
Advanced Proteome's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Advanced Proteome Price To Earning | 2.98 X |
Most of Advanced Proteome's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Proteome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Advanced Proteome Therapeutics has a Price To Earning of 2.98 times. This is 88.47% lower than that of the Biotechnology sector and 39.55% lower than that of the Health Care industry. The price to earning for all United States stocks is 89.62% higher than that of the company.
Advanced Proteome Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Advanced Proteome's current stock value. Our valuation model uses many indicators to compare Advanced Proteome value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Advanced Proteome competition to find correlations between indicators driving Advanced Proteome's intrinsic value. More Info.Advanced Proteome Therapeutics is number one stock in return on asset category among its peers. It also is the top company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Advanced Proteome's earnings, one of the primary drivers of an investment's value.About Advanced Proteome Financial Statements
Advanced Proteome stakeholders use historical fundamental indicators, such as Advanced Proteome's revenue or net income, to determine how well the company is positioned to perform in the future. Although Advanced Proteome investors may analyze each financial statement separately, they are all interrelated. For example, changes in Advanced Proteome's assets and liabilities are reflected in the revenues and expenses on Advanced Proteome's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Advanced Proteome Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation. Advanced Proteome operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.